Christophe Boetsch

CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity

Isabelle Solomon, Maria Amann, Anne Goubier et al. · Nature Cancer · 2020 · 184 citations · Full text

Cancer Immunosurveillance, T-regulatory Cell, Immunology +10

First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors

Manuel Hidalgo, Maria Martinez‐García, Christophe Le Tourneau et al. · Clinical Cancer Research · 2017 · 99 citations

Prediction of the Optimal Dosing Regimen Using a Mathematical Model of Tumor Uptake for Immunocytokine-Based Cancer Immunotherapy

Benjamin Ribba, Christophe Boetsch, Tapan K. Nayak et al. · Clinical Cancer Research · 2018 · 78 citations · Full text

The McCAVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC)

Johanna C. Bendell, Tamara Saurí, Antonio Cubillo Gracián et al. · The Oncologist · 2019 · 43 citations · Full text

Safety, PK/PD, and anti-tumor activity of RO6874281, an engineered variant of interleukin-2 (IL-2v) targeted to tumor-associated fibroblasts via binding to fibroblast activation protein (FAP).

Morten Mau‐Sørensen, Willeke Ros, María E. Rodríguez-Ruiz et al. · Journal of Clinical Oncology · 2018 · 40 citations

Engineered Variant, Immunology, Outpatient Setting +23